Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Desoximetasone
Drug ID BADD_D00620
Description A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Marketing Status approved
ATC Code D07AC03; D07XC02
DrugBank ID DB00547
KEGG ID D03697
MeSH ID D003899
PubChem ID 5311067
TTD Drug ID D0CZ1Q
NDC Product Code 45802-496; 51672-5204; 63629-8642; 68180-949; 70771-1166; 40032-024; 0168-0180; 70771-1437; 50090-5571; 51672-1270; 51672-1396; 63187-646; 71205-271; 64980-326; 51672-1261; 0472-0478; 72578-091; 0168-0151; 45802-495; 63629-8702; 68180-946; 68180-948; 0472-0479; 68180-950; 68462-531; 22552-0008; 51672-5202; 51672-5205; 51672-5281; 63629-8641; 64980-327; 72578-095; 51672-1352; 51672-5203; 53002-9280; 46439-8706; 51927-0187; 51672-1271; 51672-5263; 68180-944; 82298-112; 45802-807; 51672-1262
UNII 4E07GXB7AU
Synonyms Desoximetasone | Desoxymethasone | 17-Desoxymethasone | 17 Desoxymethasone | Deoxydexamethasone | Topicort | Stiedex | A-41304 | A 41304 | A41304 | Ibaril | Topisolon | Flubason | Topicorte | Desoxi
Chemical Information
Molecular Formula C22H29FO4
CAS Registry Number 140218-14-0
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)CO)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Uveitis10.02.01.023; 06.04.03.003--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.030--Not Available
Multiple sclerosis relapse17.16.01.003--Not Available
Fibromyalgia15.05.02.002--Not Available
Skin maceration23.03.03.016--Not Available
Joint range of motion decreased15.01.02.006--
Poor venous access24.03.02.017--Not Available
Seasonal allergy06.04.01.013; 22.04.04.008; 10.01.04.001--Not Available
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.011--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Emotional distress19.04.02.008--Not Available
General physical health deterioration08.01.03.018--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Dysstasia08.01.03.089; 17.02.02.012; 15.03.05.011--Not Available
Ear discomfort04.03.01.005--Not Available
Ocular discomfort06.08.03.008--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Secretion discharge08.01.03.019--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Haemorrhage24.07.01.002--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.11.01.003--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages